1.5
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities…
Drug regulation involves controlling the use of drugs through safety and efficacy evaluations by regulatory bodies.
Unfortunately, several tragic incidents mark the history of drug regulation.
In the Elixir Sulfanilamide tragedy, toxic diethyl glycol used in a sweet-tasting medication resulted in numerous deaths. This tragedy led to the passage of the Food, Drug, and Cosmetic Act in 1938.
Under this act, drug companies were required to demonstrate the safety of their products through toxicity studies and accurate labeling. However, proof of efficacy was not mandatory.
The thalidomide disaster led to the passage of the Kefauver-Harris Amendments in 1962.
This required manufacturers to provide evidence of a drug's efficacy and safety through the risk-to-benefit ratio. Research on animals was also made mandatory before running human trials.
The resulting data were submitted to the FDA as an application for an IND.
To expedite the drug approval process, the FDA took measures such as accelerating the review of drugs used for fatal illnesses and getting more actively involved in drug development.
View the full transcript and gain access to JoVE Core videos
Q1: What tragic event led to the Food, Drug, and Cosmetic Act of 1938?
The Elixir Sulfanilamide tragedy prompted the Food, Drug, and Cosmetic Act. A sweet-tasting medication containing the toxic compound diethyl glycol caused numerous deaths. This disaster established the requirement that drug companies demonstrate product safety through toxicity studies and accurate labeling before market approval.
Q2: How did the Kefauver-Harris Amendments change drug approval requirements?
The Kefauver-Harris Amendments of 1962, enacted after the thalidomide disaster, mandated manufacturers to provide evidence of both drug efficacy and safety using the risk-to-benefit ratio. Animal research became mandatory before human trials. This represented a major shift from earlier regulations that required only safety demonstration without efficacy proof.
Q3: What is an IND application in the drug approval process?
An IND (Investigational New Drug) application is a submission to the FDA containing data from preclinical development and animal research. Manufacturers compile results from toxicity studies and animal trials into this application before proceeding to human testing. The IND serves as the formal request to begin clinical investigation of a new drug candidate.
Q4: Why was animal research made mandatory in drug development?
Animal research became mandatory following the thalidomide disaster to establish safety and efficacy before exposing humans to experimental drugs. This requirement ensures that preliminary toxicity and effectiveness data are collected in controlled laboratory settings. Animal studies now form a critical component of the regulatory pathway preceding human clinical trials.
Q5: What measures did the FDA implement to expedite drug approval?
The FDA accelerated the drug approval process by prioritizing review of medications for fatal illnesses and becoming more actively involved in drug development. These measures aimed to reduce approval timelines while maintaining safety and efficacy standards. The FDA's proactive engagement helps streamline the pathway from discovery to patient access for critical therapies.
Q6: What was the key difference between the 1938 and 1962 drug regulations?
The 1938 Food, Drug, and Cosmetic Act required only safety demonstration through toxicity studies and labeling. The 1962 Kefauver-Harris Amendments added the mandatory requirement for efficacy evidence evaluated through risk-to-benefit analysis. This evolution reflected lessons from drug disasters and established more comprehensive regulatory standards for pharmaceutical approval.
Q7: How does drug regulation protect public health?
Drug regulation controls medication use through systematic safety and efficacy evaluations by regulatory bodies like the FDA. Requirements include toxicity studies, animal research, risk-to-benefit assessment, and accurate labeling. These safeguards prevent harmful substances from reaching patients and ensure that approved drugs demonstrate both safety and therapeutic effectiveness.